A Trial of Evonail® Solution for Prevention or Treatment of Onycholysis

A Prospective Randomized Controlled Trial of Evonail® Solution for Prevention or Treatment of Onycholysis in Breast Cancer Patients Who Received Neoadjuvant/Adjuvant Docetaxel Chemotherapy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02670603

Enrollment

100

Registered

2016-02-02

Start date

2015-08-31

Completion date

2016-09-30

Last updated

2017-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Docetaxel Chemotherapy

Brief summary

This study is a prospective randomized controlled study of EVONAIL® solution for prevention or treatment of onycholysis in patients with breast cancer receiving docetaxel chemotherapy.

Interventions

DRUGEVONAIL® solution

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

SINGLE (Outcomes Assessor)

Masking description

This study is open-labeled study. But outcome would be assessed the statistician who did not involve this study with blind data.

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Yes

Inclusion criteria

* Patients with breast cancer receiving adjuvant/neoadjuvant docetaxel chemotherapy

Exclusion criteria

* Patients with breast cancer receiving palliative docetaxel chemotherapy * Patients having onycholysis before docetaxel treatment

Design outcomes

Primary

Measure	Time frame
The incidence of onycholysis Gr 2 or more	12weeks

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026